Agilent Announces SureSelect XT HS2 RNA Reagent Kit, a Library Prep and Target Enrichment Solution for RNA-Seq
September 01 2020 - 8:00AM
Business Wire
Streamlined solution for RNA and DNA-seq to simplify clinical
NGS
Agilent Technologies Inc. (NYSE: A) today announced the release
of the SureSelect XT HS2 RNA Reagent Kit. This solution features a
modular design that enables a simple and parallel approach for both
RNA and DNA samples, allowing customers to streamline and
consolidate their workflow without losing time optimizing different
kits for different sample types. It marks the latest development in
Agilent’s ongoing effort to improve NGS applications and workflows,
leveraging the performance and versatility of XT HS2 chemistry.
“Agilent has innovated library prep and target enrichment for
RNA and DNA into a parallel sequencing workflow,” says Kevin
Meldrum, vice president, and general manager of Agilent’s Genomics
Division. “The new streamlined solution will help simplify the
technician’s workday and provides fast turnaround time of only 1–2
days for library preparation regardless of sample type.”
The SureSelect XT HS2 RNA Reagent Kit expands the NGS
applications of the XT HS2 chemistry, allowing customers to
accurately profile gene expression and detect RNA fusions using
low-input FFPE samples. The addition of this kit distinguishes
Agilent as the leading vendor in the industry to offer a complete
end-to-end NGS sample prep solution from sample QC, library prep
and target enrichment, automation, and data analysis, backed by a
simple and easy one-stop-shop ordering and support experience.
The kit is anticipated to significantly improve efficiency,
especially in labs processing both DNA and RNA samples for NGS
applications. “This new solution delivers fast turnaround time so
we can spend less time on wet lab work and focus more on results,”
says Georges A. Belderbos, head of marketing and sales for NEO New
Oncology GmbH. “FFPE compatibility and a parallel workflow to the
XT HS2 DNA kit simplified implementation so we could start
detecting RNA fusions quickly.”
SureSelect XT HS2 RNA supports 384 unique dual sample indexes
(UDIs) and allows customers to multiplex hundreds of samples in one
sequencing run without worrying about index hopping. It features
molecular barcodes, for more efficient deduplication of sequencing
reads and more accurate gene expression analysis. SureSelect XT HS2
RNA may be purchased with Ampure and Streptavidin beads as part of
a complete kit.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200901005282/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024